Pharmaceutical intelligence for immunology therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Recent signals(2)

StrategyJuly 14, 2026

Human factors study validates Bmab 1200 autoinjector for ustekinumab delivery

The Bmab 1200 autoinjector showed high usability and safety in a human factors validation study with 100% successful unaided injections.

ClinicalJune 20, 2026

Study on Genetic Disorders of the Immune System Launched by NIAID

NIAID is conducting a study to evaluate individuals with specific immune system disorders, involving extensive genetic and medical assessments.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

Clinical

June 20, 2026

Study on Genetic Disorders of the Immune System Launched by NIAID

NIAID is conducting a study to evaluate individuals with specific immune system disorders, involving extensive genetic and medical assessments.

Competitive activity

No signals indexed for this entity yet.

Assets

NIAID →

ustekinumab →

Therapeutic areas

Genetic Disorders →

Immunology →

Psoriasis and Autoimmune Diseases →

Indications

Genetic Disorders →

Psoriasis and Autoimmune Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.